Navigation Links
ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program
Date:4/8/2009

FREDERICK, Md., April 8 /PRNewswire/ -- ImQuest Life Sciences presented their latest biological results supporting the continued development of their novel small molecule piperazine compound for the treatment of solid tumors at the Targeted Cancer Therapeutics meeting held in Whistler, British Columbia. The presentation highlighted advances in the development of ImQuest's lead microtubule inhibitor, IQP-0304. The piperazines demonstrate potent antiproliferative activity against a variety of tumor cell types (prostate, lung, ovary, colon, CNS, melanoma, and hematopoietic lineages) by disruption of cell cycle progression and induction of apoptosis with a secondary anti-angiogenic activity as a consequence of the cytoskeletal disruption. The unique activity, novel structure, potent in vivo efficacy in murine xenograft models, as well as a favorable toxicity profile, potential for oral bioavailability and straight-forward cGMP manufacturing suggest that IQP-0304 might be an important addition to the currently available therapeutic regimens used to treat solid tissue malignancies. Dr. Nick Kaludov, Ph.D., Director of Scientific Operations, presented the new findings which also included toxicology and toxicokinetic evaluations.

"These results highlight the significant potential of the piperazines as highly potent and broadly active chemotherapeutic agents and provide additional rationale for their expedited development," said Dr. Robert W. Buckheit Executive Vice President and Chief Scientific Officer, and presentation co-author.

ImQuest Life Sciences, a privately held U.S. company located in Frederick, Maryland specializes in the preclinical and clinical development of novel compounds for the treatment of infectious disease and cancer. ImQuest BioSciences, also located in Frederick, Maryland, is a leading provider of anti-infective and anti-cancer drug and vaccine development services to the biotechnology and pharmaceutical industry.

    For further information regarding this press release please contact:
    Robert W. Buckheit, Jr., Ph.D.
    Executive Vice President and Chief Scientific Officer
    ImQuest Life Sciences, Inc.
    301-696-0274
    rbuckheit@imquest.com


'/>"/>
SOURCE ImQuest Life Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImQuest Presents Data on the Anti-Hepatitis B Virus Activity of Pyrimidinediones at the 13th ISVHLD Meeting in Washington D.C.
2. ImQuest Presentations at CROI Report Significant Advances in Therapeutic and Microbicide Product Development Programs
3. ImQuest Presents IND-Enabling Safety Pharmacology and Pharmacokinetic Data for the Therapeutic HIV Compound IQP-0410 at Conference on Retroviruses and Opportunistic Infections
4. ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission
5. ImQuest Awarded SBIR Grant to Define the Mechanism of Action of Their Lead Anti-HIV Therapeutic Compound IQP-0410
6. Frost & Sullivan Hosts Presentation on MicroRNAs: From Stem Cells and Cancer to Diagnostics and Therapeutics
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Citi Conference
8. Encision Enters Into Sales Representation Agreement With Caldera Medical
9. Spectral announces presentations at the 29TH International Symposium on Intensive Care and Emergency Medicine focusing on the role of endotoxin
10. Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference
11. Alexzas Corporate Presentation to be Webcast at the Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Diego, CA (PRWEB) , ... April 20, 2017 , ... ... management of clinical trials worldwide, announced today that they were named one of the ... , which covers the latest developments in the pharmaceutical industry. , “We take pride ...
(Date:4/19/2017)... ... 18, 2017 , ... The Vibrating Orifice Aerosol Generator (VOAG) ... monodisperse droplets of known diameters for research applications such as for calibrating droplet ... drying monodisperse droplets. , The VOAG requires forcing liquid out of an ...
(Date:4/19/2017)... ... April 19, 2017 , ... ThermaGenix, the PCR Improvement Company, ... to several other early achievements at ThermaGenix, including the business formation and licensing ... ThermaGenix will use proceeds from the Series A-1 round to:, ...
(Date:4/19/2017)... and WESTMINSTER, Colo. , April ... an industry-leading specialty finance firm that provides senior ... today announced the closing of a $20 million ... a privately-held orthobiologics company engaged in the development ... the treatment of orthopedic injuries. Cerapedics, ...
Breaking Biology Technology:
(Date:4/18/2017)... -- Socionext Inc., a global expert in SoC-based imaging and computing solutions, ... which features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ... will be showcased during the upcoming Medtec Japan at Tokyo Big ... Las Vegas Convention Center April 24-27. ... Click here for an image of ...
(Date:4/13/2017)... SANTA MONICA, Calif. , April 13, 2017 /PRNewswire/ ... New York will feature emerging and ... Innovation Summits. Both Innovation Summits will run alongside the ... variety of speaker sessions, panels and demonstrations focused on ... east coast,s largest advanced design and manufacturing event will ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
Breaking Biology News(10 mins):